

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10	
<i>EV 704618433 U.S.</i> Express Mail Label Number	<i>June 29, 2005</i> Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF:

CHIQUET-EHRISMANN, ET AL.

INTERNATIONAL APPLICATION NO: PCT/EP03/003150

FILED: 26 MARCH 2003

U.S. APPLICATION NO: 10/509,009

35 USC §371 DATE: Not Yet Known

FOR: TENASCIN-W COMPOSITIONS AND USES THEREOF

MAIL STOP: PCT

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

LETTER CORRECTING OFFICIAL FILING RECEIPT

Sir:

The official Filing Receipt received in the above-identified application erroneously lists the **Assignment for Published Patent Application**. Please issue a corrected Filing Receipt listing the Assignee as follows:

--Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland. --

A copy of the Filing Receipt with the correction noted is enclosed.

No fee is believed to be required by this request for a corrected Filing Receipt.

Respectfully submitted,

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(617) 871-3346
Date: June 29, 2005


John T. Prince
Attorney for Applicants
Reg. No. 43,019

enascin-w compositions and uses thereof ✓
Preliminary Class

435

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

BEST AVAILABLE COPY BEST AVAILABLE COPY

RECEIVED
JUN 16 2005



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/509,009	05/03/2005	1645	2400	1011237 AFMI		52	12

1095
NOVARTIS
CORPORATE INTELLECTUAL PROPERTY
ONE HEALTH PLAZA 104/3
EAST HANOVER, NJ 07936-1080

JTP



CONFIRMATION NO. 1199

FILING RECEIPT



0000000016109835*

Date Mailed: 05/31/2005

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please mail to the Commissioner for Patents P.O. Box 1450 Alexandria Va 22313-1450. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Ruth Chiquet-Ehrismann, Reinach, SWITZERLAND; ✓
Arnaud Scherberich, Riedisheim, FRANCE; ✓

Assignment For Published Patent Application

Novartis International AG, Basel, SWITZERLAND

Zweigniederlassung Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland

Power of Attorney: The patent practitioners associated with Customer Number 1095.

Domestic Priority data as claimed by applicant

This application is a 371 of PCT/EP03/03150 03/26/2003 ✓

Foreign Applications

UNITED KINGDOM 0207224.7 03/27/2002

Projected Publication Date: 09/01/2005

Non-Publication Request: No

Early Publication Request: No

Title